Compare Ascendis Pharma A/S (ASND) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Direxion Daily S&P 500 Bull 3X Shares trades at $276.54. Which is the better fit depends on your goals.
| ASND | SPXL | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $288.04 |
52-Week Low | $163.32 | $170.20 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SPXL trades at $279.18, up 1.22% on the day, with a bullish technical signal from moving averages. The stock faces resistance near $281-$285 while supported at $271-$274. Recent news highlights AI-driven market optimism but notes Fed policy and earnings as key near-term catalysts. A dividend of $0.52 is scheduled for June 30, 2026.
Outlook remains positive given strong AI sector momentum, though stretched valuations and Fed tightening risks warrant caution. Earnings growth and sector rotation will dictate direction, with technical indicators suggesting potential consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
